As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues ...

南旧金山 - 专注于神经退行性疾病的生物科技公司Alector, Inc.

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

Investing.com -- Alector Inc.宣布，其用于早期阿尔茨海默症治疗的AL002药物的二期临床试验未能达到减缓疾病进展的主要目标。受此消息影响，该公司股价在盘后交易中暴跌32%。 这家生物制药公司表示，由于试验未能达到主要终点，将终止AL002的长期延伸研究。针对这一发展，Alector还透露计划裁减约17%的员工。

Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease.

Alec­tor re­port­ed a Phase 2 fail­ure for an Ab­b­Vie-part­nered Alzheimer’s pro­gram Mon­day af­ter­noon and said it will ...

It's impossible to miss, but at the same time it's 'hard to see'. However it's unquestionably the 'biggest issue' for this Australian capital, critics say. One Australian hunter said in his 50 ...